Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Head & Neck|January 29, 2014
Management of invasive well-differentiated thyroid cancer: an American Head and Neck Society consensus statement. AHNS consensus statementMaisie L Shindo, Salvatore M Caruana, Emad Kandil, et al.
Oral Oncology|October 14, 2023
Circulating tumor-tissue modified HPV DNA testing in the clinical evaluation of patients at risk for HPV-positive oropharynx cancer: The IDEA-HPV studySana Batool, Rosh K V Sethi, Annette Wang, et al.
Scientific Reports|November 20, 2020
LOXL2 promotes aggrecan and gender-specific anabolic differences to TMJ cartilageMustafa M Tashkandi, Saqer F Alsaqer, Thabet Alhousami, et al.
Breast Cancer Research and Treatment|April 20, 2022
Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast)Elizabeth O'Donnell, Yael Shapiro, Amy Comander, et al.
BMC Oral Health|May 18, 2021
A preliminary assessment of guideline adherence and clinical variation in oral cancer treatment: a MarketScan database studyAntoine Eskander, Axel Sahovaler, Jennifer Shin, et al.
Molecular Cancer Research : MCR|February 2, 2022
Inhibition of LSD1 Attenuates Oral Cancer Development and Promotes Therapeutic Efficacy of Immune Checkpoint Blockade and YAP/TAZ InhibitionThabet Alhousami, Michael Diny, Faiza Ali, et al.
Breast Cancer Research and Treatment|September 17, 2018
Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancerLaura Spring, Andrzej Niemierko, Stephanie Haddad, et al.
Journal of Cardiovascular Electrophysiology|March 18, 2025
Outcomes in Patients With Mitral Annular Disjunction and an Implantable-Cardioverter DefibrillatorFatima M Ezzeddine, Jee Won Jennifer Shin, Konstantinos C Siontis, et al.
Blood Advances|February 11, 2026
Halofuginone Suppresses Hepcidin by a Heparan Sulfate-dependent Mechanism to Treat Iron Disorders in MiceStephanie Leal, Andrea Denardo, Anna Van Echten, et al.
NPJ Breast Cancer|January 8, 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)Laura M Spring, Lauren Scarpetti, Arielle J Medford, et al.
Pageof 5